Acurx Pharmaceuticals, Inc. (ACXP)
| Market Cap | 13.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.44M |
| Shares Out | 16.89M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,690 |
| Open | 0.790 |
| Previous Close | 0.759 |
| Day's Range | 0.760 - 0.835 |
| 52-Week Range | 0.720 - 5.280 |
| Beta | -1.85 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+1,354.55%) |
| Earnings Date | Nov 12, 2024 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ACXP stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecu...
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback ...
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook
The board of Acurx Pharmaceuticals has approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
STATEN ISLAND, N.Y. , Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of anti...
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy An update of ibezapolstat Ph2b clinical and microbiome results was p...
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, ...
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
STATEN ISLAND, N.Y. , Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of anti...
Acurx Ready To Expand Pipeline With Anthrax Treatment
Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 tri...
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatme...
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
STATEN ISLAND, N.Y. , Oct. 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotic...
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics...
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The ...
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week NEW YORK, NY / ACCESSWIRE / October 11, 2024 / New to The Street, the leading platform for showc...
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
New analyses extend data on beneficial effects of ibezapolstat on the gut microbiome Confirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic concentrations S...
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antib...
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
September 9-11, 2024 STATEN ISLAND, N.Y. , Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C.
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Conference Call August 9, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President & CEO Robert DeLuccia - Executive ...
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antib...
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treat...
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive ...
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
Agreement with FDA reached on key elements to move forward with our international Phase 3 clinical trial program Agreement also reached with FDA on complete non-clinical and clinical development plan ...
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
STATEN ISLAND, N.Y. , May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of a...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
STATEN ISLAND, N.Y. , May 2, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...